How Amgen’s Nplate, Vectibix, and Neupogen Performed in 1Q18
In 1Q18, Amgen’s (AMGN) Nplate revenue grew 16% YoY (year-over-year) to $179 million from $154 million, primarily driven by unit demand.
May 7 2018, Updated 9:01 a.m. ET
Nplate revenue trends
In 1Q18, Amgen’s (AMGN) Nplate revenue grew 16% YoY (year-over-year) to $179 million from $154 million, primarily driven by unit demand. It grew ~8% QoQ (quarter-over-quarter).
In US and international markets, Nplate generated revenue of $112 million and $67 million, respectively. Nplate is used to treat chronic immune thrombocytopenia. Novartis’s (NVS) Promacta is a market peer.
Vectibix revenue trends
In 1Q18, Vectibix revenue grew 15% YoY to $169 million from $147 million, primarily driven by unit demand. It grew ~6% QoQ. In US and international markets, Vectibix generated revenue of $75 million and $94 million, respectively. Vectibix is used to treat wild-type RAS metastatic colorectal cancer.
Neupogen revenue trends
In 1Q18, Neupogen revenue fell 30% YoY to $103 million from $148 million. It fell ~18% QoQ. In US and international markets, Neupogen generated revenue of $65 million and $38 million, respectively, compared with $101 million and $48 million in 1Q17.
Neupogen is used to treat low blood neutrophils. In the short-acting segment, Neupogen has a ~40% US market share. Neupogen competes with Teva Pharmaceutical’s (TEVA) Lonquex, Sanofi’s (SNY) Leukine, and Novartis’s (NVS) Zarxio.
